Drug Type Small molecule drug |
Synonyms BTA 243, CL 316243, CL-316243 |
Target |
Action agonists |
Mechanism β3-adrenergic receptor agonists(Beta-3 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H20ClNNa2O7 |
InChIKeyUVJBVPHQFYWKJL-CFOQQKEYSA-N |
CAS Registry138908-40-4 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diabetes Mellitus, Type 2 | Phase 2 | United States | - | |
| Diabetes Mellitus, Type 2 | Phase 2 | European Union | - | - |
| Diabetes Mellitus, Type 2 | Phase 2 | - | - | |
| Obesity | Phase 2 | United States | - | |
| Obesity | Phase 2 | European Union | - | - |
| Obesity | Phase 2 | - | - | |
| Urinary Bladder, Overactive | Preclinical | United States | - |





